Logo

Agilent Enters into a Collaboration Agreement with Incyte to Advance the Development of Companion Diagnostics

Share this
Incyte

Agilent Enters into a Collaboration Agreement with Incyte to Advance the Development of Companion Diagnostics

Shots:

  • Agilent signed a collaboration agreement with Incyte to leverage Agilent’s expertise in the development of companion diagnostics (CDx) for the development and commercialization of hematology and oncology portfolio
  • The collaboration integrates both companies to collaborate on CDx development programs. Through the agreement, Agilent expects to expand its companion diagnostic portfolio with novel biomarkers
  • Moreover, the collaboration gives Incyte the leverage to use Agilent’s expertise in IVD assay development, global regulatory approvals & commercialization to support clinical trials, potential registration & commercialization of CDx in the US & EU

Ref: Agilent | Image: Incyte

Related News:- Incyte Presents Positive 52-Week P-IIb Trial Results of Povorcitinib (INCB54707) for Extensive Nonsegmental Vitiligo at EADV 2023

PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com

Click here to­ read the full press release 

Shivani Chandra

Shivani was a content writer at PharmaShots. She has a keen interest in recent innovations in the life sciences industry. She was covering news related to Product approvals, clinical trial results, and updates. We can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions